Danirixin
Danirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8) ; blocks the CD11b upregulation with pIC50 of 6.05 and 6.3, respectively, in rat and human whole-blood studies; blocks the influx of neutrophils into the lung in vivo in rats following aerosol lipopolysaccharide (ED50=1.4 mg/kg) ; orally active.COPD Phase 2 Clinical (In Vitro) :Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.
Product Specifications
CAS Number
954126-98-8
Product Name Alternative
GSK-1325756
Purity
>98% (HPLC)
Solubility
DMSO: 8 mg/mL
Smiles
ClC (C (S ([C@H]1CCCNC1) (=O) =O) =C2O) =CC=C2NC (NC3=CC=CC (F) =C3C) =O
Molecular Formula
C19H21ClFN3O4S
Molecular Weight
441.9041
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Urea, N-[4-chloro-2-hydroxy-3-[ (3S) -3-piperidinylsulfonyl]phenyl]-N'- (3-fluoro-2-methylphenyl) -
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
RBMY1A1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)
